Sort
48,018 grants matching “immunotherapy”
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
$583,603Elad Ziv · University Of California, San Francisco · R01 · FY2022 · CA
Mechanisms of treatment failure in chimeric antigen receptor T cell therapy
$583,532Brian Till · Fred Hutchinson Cancer Research Center · R01 · FY2019 · CA
Project 1: Durable impact of COVID on innate and adaptive immunity
$583,489Michela Locci · Massachusetts General Hospital · U19 · FY2025 · AI
Exploring DNA damage response pathways as targets for cancer therapy
$583,430Junjie Chen · University Of Tx Md Anderson Can Ctr · R35 · FY2022 · CA
PAG is a novel target in immunotherapy
$583,390Adam Mor · Columbia University Health Sciences · R01 · FY2020 · AI
AIDS CLINICAL TRIALS
$583,355Seattle Children'S Hospital · U01 · FY2000 · AI
Metformin for chemoprevention of lung cancer in obese subjects at high risk
$583,338Saikrishna Yendamuri · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA
PET Studies of Serotonin and Amyloid in MCI
$583,276Gwenn S Smith · Johns Hopkins University · R01 · FY2014 · AG
Induction of autosis to overcome resistance in adoptive cell therapy for solid tumors
$583,266Yong Lu · Methodist Hospital Research Institute · R01 · FY2023 · CA
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy
$583,258T.-C. Wu · Johns Hopkins University · R01 · FY2021 · CA
Protein kinase C signaling in prostate cancer health disparities
$583,194Marcelo Gabriel Kazanietz · University Of Miami School Of Medicine · R01 · FY2025 · CA
Finding the optimal balance of immunotherapy efficacy and toxicity.
$583,185David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2021 · AI
Enhancing Pathogen-specific Memory CD8+ T cell Responses in Vivo
$583,143Gregoire Stephane Lauvau · Albert Einstein College Of Medicine · R01 · FY2022 · AI
Validation of a novel 3D culture platform for TNBC treatment selection
$583,104Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2024 · CA
Dendritic Cell mediated induction of Anti-HCV immunity
$583,096Nina Bhardwaj · New York University School Of Medicine · R01 · FY2006 · AI
Immune Therapy for Brain Metastasis
$583,091Lucia Beatrice Jilaveanu · Yale University · R01 · FY2023 · CA
TECH Core
$583,074Kevin William Eliceiri · University Of Minnesota · U54 · FY2025 · CA
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
$583,071Gerardo Guillermo Mackenzie · University Of California At Davis · R01 · FY2023 · CA
Developing a Human in Mouse Cancer Model with a Completely Humanized Stroma
$583,011Ronald J Buckanovich · Magee-Women'S Res Inst And Foundation · R01 · FY2019 · CA
PD-1 modulation of SIV specific CD4 and CD8 T cell responses
$582,964Francois J Villinger · Emory University · R01 · FY2009 · AI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.
$582,940Mary L. Disis · University Of Washington · R01 · FY2009 · CA
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
$582,917Tyler J. Curiel · University Of Texas Hlth Science Center · R01 · FY2018 · CA
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
$582,888Brendan D Curti · Providence Portland Medical Center · R01 · FY2023 · CA
Role of IRF2 in cancer immune evasion and immunotherapy
$582,872Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2020 · CA
Role of IRF2 in cancer immune evasion and immunotherapy
$582,872Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · CA